Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Publication year range
2.
Can J Cardiol ; 32(5): 680-686.e4, 2016 05.
Article in English | MEDLINE | ID: mdl-27118295

ABSTRACT

Aging is considered the most important nonmodifiable risk factor for cardiovascular disease and death after age 28 years. Because of demographic changes the world population is expected to increase to 9 billion by the year 2050 and up to 12 billion by 2100, with several-fold increases among those 65 years of age and older. Healthy aging and prevention of aging-related diseases and associated health costs have become part of political agendas of governments around the world. Atherosclerotic vascular burden increases with age; accordingly, patients with progeria (premature aging) syndromes die from myocardial infarctions or stroke as teenagers or young adults. The incidence and prevalence of arterial hypertension also increases with age. Arterial hypertension-like diabetes and chronic renal failure-shares numerous pathologies and underlying mechanisms with the vascular aging process. In this article, we review how arterial hypertension resembles premature vascular aging, including the mechanisms by which arterial hypertension (as well as other risk factors such as diabetes mellitus, dyslipidemia, or chronic renal failure) accelerates the vascular aging process. We will also address the importance of cardiovascular risk factor control-including antihypertensive therapy-as a powerful intervention to interfere with premature vascular aging to reduce the age-associated prevalence of diseases such as myocardial infarction, heart failure, hypertensive nephropathy, and vascular dementia due to cerebrovascular disease. Finally, we will discuss the implementation of endothelial therapy, which aims at active patient participation to improve primary and secondary prevention of cardiovascular disease.


Subject(s)
Aging , Antihypertensive Agents/therapeutic use , Hypertension/prevention & control , Hypertension/physiopathology , Vascular Stiffness , Dementia, Vascular/complications , Diabetes Complications/prevention & control , Dyslipidemias/complications , Heart Failure/complications , Humans , Hypertension/therapy , Hypertension, Renal/complications , Kidney Failure, Chronic/complications , Myocardial Infarction/complications , Nephritis/complications , Risk Factors
3.
Prostaglandins Other Lipid Mediat ; 89(3-4): 89-97, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19442754

ABSTRACT

GPR30, now named GPER1 (G protein-coupled estrogen receptor1) or GPER here, was first identified as an orphan 7-transmembrane G protein-coupled receptor by multiple laboratories using either homology cloning or differential expression and subsequently shown to be required for estrogen-mediated signaling in certain cancer cells. The actions of estrogen are extensive in the body and are thought to be mediated predominantly by classical nuclear estrogen receptors that act as transcription factors/regulators. Nevertheless, certain aspects of estrogen function remain incompatible with the generally accepted mechanisms of classical estrogen receptor action. Many recent studies have revealed that GPER contributes to some of the actions of estrogen, including rapid signaling events and rapid transcriptional activation. With the introduction of GPER-selective ligands and GPER knockout mice, the functions of GPER are becoming more clearly defined. In many cases, there appears to be a complex interplay between the two receptor systems, suggesting that estrogen-mediated physiological responses may be mediated by either receptor or a combination of both receptor types, with important medical implications.


Subject(s)
Estrogens/metabolism , Receptors, G-Protein-Coupled/physiology , Signal Transduction , Animals , Estrogen Receptor Modulators/metabolism , Female , Gene Expression Regulation , Humans , Ligands , Male , Neoplasms/metabolism , Phytoestrogens/metabolism , Pregnancy , Receptors, Estrogen , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/deficiency , Selective Estrogen Receptor Modulators/metabolism
4.
Eur J Pharmacol ; 434(1-2): 1-7, 2002 Jan 02.
Article in English | MEDLINE | ID: mdl-11755158

ABSTRACT

This study investigated whether human vascular smooth muscle cell proliferation induced by native low-density lipoprotein (LDL) is affected by green tea catechins. Furthermore, the effects of native LDL on extracellular signal-regulated kinase (ERK) 1/2 activity were determined. Cell proliferation stimulated by native LDL was concentration-dependently inhibited by epigallocatechin, epigallocatechin-3-gallate, green tea polyphenon, and the nonspecific antioxidant N-acetylcysteine (P<0.05). Combined treatment of green tea polyphenon and N-acetylcysteine markedly potentiated the effect of each drug on vascular smooth muscle cell proliferation. ERK1/2 activity was only partly inhibited by green tea catechins alone or in combination with N-acetylcysteine (P<0.05). These data suggest that green tea constituents inhibit proliferation of human vascular smooth muscle cells exposed to high levels of native LDL. Green tea constituents and antioxidants may exert vascular protection by inhibiting human vascular smooth muscle cell growth associated with hypercholesterolemia.


Subject(s)
Antioxidants/pharmacology , Catechin/pharmacology , Flavonoids , Lipoproteins, LDL/antagonists & inhibitors , Muscle, Smooth, Vascular/drug effects , Phenols/pharmacology , Polymers/pharmacology , Tea , Acetylcysteine/pharmacology , Cell Division/drug effects , Cells, Cultured , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/metabolism , Muscle, Smooth, Vascular/cytology
SELECTION OF CITATIONS
SEARCH DETAIL